Tetrahydroindolone derivatives for treatment of neurological conditions

A pharmaceutical composition comprising a compound having the following formula (I):

• wherein:
• (a) X is CH or N;
• (b) R1 is hydrogen, alkyl, aralky, heteroaralkyl, alkenyl, aralkenyl, heteroaralkenyl, aryl, or heteroaryl;
• (c) R2 is hydrogen, alkyl, aralky, aryl, or heteroaryl;
• (d) R2′ is hydrogen unless R2 is methyl, in which case R2′ is also methyl;
• (e) R3 has the following formula (III):
• wherein:
• (i) R4 is hydrogen, alkyl, halo, hydroxy, alkoxy, cyano, nitro, perfluoroalkyl, perfluoroalkoxy, or hydroxymethyl;
• (ii) R5 is hydrogen, alkyl, halo, alkoxy, cyano, nitro, perfluoroalkyl, perfluoroalkoxy, amino, aminocarbonyl, aminosulfonyl, or hydroxymethyl;
• (iii) R6 is alkyl, halo, alkoxy, perfluoroalkyl, perfluoroalkoxy, or nitro;
• (iv) R4 and R5 when taken together can form a 5 or 6 membered ring and can contain one or more heteroatoms;
• (v) R5 and R6 when taken together can form a 5 or 6 membered ring and can contain one or more heteroatoms;
• (f) L is selected from the group consisting of —(CH2)m—, where m is an integer from 1 to 6, and an alkyl substituted hydrocarbyl moiety of the formula (IV):
• wherein:
• (i) n is 0, 1 or 2;
• (ii) R7 and R8 are hydrogen, methyl or ethyl;
• (iii) R9 and R9′ are both hydrogen, methyl or ethyl;
• (iv) if n is 1 and R7 or R8 is methyl or ethyl, then R9 and R9′ are hydrogen;
• (v) if n is 1 and R7 and R8 are hydrogen, then R9 and R9′ are methyl or ethyl;
• and
• (vi) if n is 2, then R9 and R9′ are hydrogen and one or both of R7 and R8 are methyl or ethyl.
• and pharmaceutically acceptable salts and esters thereof.